🔴 UroGen Pharma is trading 5% down in pre-market — no clear catalyst identified

UroGen Pharma is trading 5.19% down at $32.00, based on supplied pre-market price context, with no clear overnight catalyst identified.

• On October 28, the company announced positive five-year JELMYTO follow-up results, including durable responses, but available coverage does not link them to the current decline.
• Healthcare was reported higher pre-market, while broader index futures were mixed to lower; neither establishes a specific cause for the stock’s move.